144925-02-0

Basic information

• Product Name: 6-chloro-9-(5′-O-trityl-β-D-ribofuranosyl)purine
• Synonyms: 6-chloro-9-(5′-O-trityl-β-D-ribofuranosyl)purine
• CAS NO: 144925-02-0
• Molecular Weight: 528.995
• Mol File: 144925-02-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6-chloro-9-(5′-O-trityl-β-D-ribofuranosyl)purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-9-(5′-O-trityl-β-D-ribofuranosyl)purine(144925-02-0)
• EPA Substance Registry System: 6-chloro-9-(5′-O-trityl-β-D-ribofuranosyl)purine(144925-02-0)

Safety Data

• Hazardous Substances Data: 144925-02-0(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 41028-66-4 1,5-anhydroribitol 
• 55726-00-6 (3R,4S,5R)-5-((trityloxy)methyl)tetrahydrofuran-2,3,4-triol 
• 87-42-3 6-chloropurine 
• 2004-06-0 6-Chloropurine riboside 

Downstream Products

• 18048-85-6 5'-O-(triphenylmethyl)adenosine 
• 2004-06-0 6-Chloropurine riboside 
• 58-61-7 adenosine 
• 339196-23-5 thiocarbonic acid O-[5-(6-amino-purin-9-yl)-4-fluoro-2-trityloxymethyl-tetrahydro-furan-3-yl] ester O-(4-fluoro-phenyl) ester 
• 234436-48-7 9-[3-O-benzoyl-5-O-(triphenylmethyl)-β-D-ribofuranosyl]-6-chloro-9H-purine 
• 239811-12-2 Benzoic acid (2R,3R,4R,5R)-2-(6-chloro-purin-9-yl)-4-hydroxy-5-trityloxymethyl-tetrahydro-furan-3-yl ester 
• 265987-43-7 9-(5-O-trityl-3-O-methylthiothiocarbonyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine 
• 339196-22-4 5'-O-trityl-3'-O-benzoyl-2'-O-trifluoromethanesulfonyl-6-chloropurine riboside 
• 234436-50-1 Benzoic acid (2R,3R,4R,5R)-5-(6-chloro-purin-9-yl)-4-(imidazole-1-sulfonyloxy)-2-trityloxymethyl-tetrahydro-furan-3-yl ester 
• 234436-54-5 9-(3-O-phenoxythiocarbonyl-5-O-trityl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 
• 234436-49-8 9-[3-O-benzoyl-2-deoxy-2-fluoro-5-O-(triphenylmethyl)-β-D-arabinofuranosyl]-6-chloro-9H-purine 
• 239811-11-1 9-(5-O-trityl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 
• 234436-55-6 9-[2,3-dideoxy-2-fluoro-5-O-(triphenylmethyl)-β-D-threo-pentofuranosyl]-9H-purine-6-amine 
• 110143-10-7 iodenosine 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION COMPRISING NOVEL AZOLOPYRIMIDINE HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT

The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophylaxis or treatment of cancer of the present invention can be used as a small molecular immunotherapy anticancer agent which modulates an adenosine pathway by comprising the azolopyrimidine heterocyclic compound.

INHIBITORS OF E1 ACTIVATING ENZYMES

This invention relates to compounds that inhibit El activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

An industrial process for synthesizing lodenosine (FddA)

Two industrial synthetic approaches to Lodenosine (1, FddA, 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl) adenine) via a purine riboside or a purine 3′-deoxyriboside are described. Several novel applications of deoxygenation and fluorination methods are compared considering reaction yields, economy, safety and environmental concerns.